الفهرس 
M AGNESIUM S ULFATE (M GSO 4)Only 14 pages are availabe for public view
 |  | from | 147 |  |  |
| | | from | 147 | | |
Abstract
Background: Preterm birth can be considered a complex problem in relation to baby’s development to the parents’ practical and emotional experience and to mother child interaction. The poor developmental outcomes of preterm infants have been well documented.
Objective: To evaluate the use of MgSO4 in preterm deliveries as bolus versus bolus and infusion protocols in terms of fetal neuroprotection and fetal wellbeing.
Methods: This randomized clinical trial was conducted on department of Obstetrics and Gynecology – Ain Shams University Maternity Hospital. 88 preterm labor women with imminent preterm birth between 28 and 33 weeks of gestation were recruited. Tocolytics were started to all women in the form of Nifidipine (Epilat 10 mg tid). 4 gm IV bolus were given to all women followed by a 1 gm / hr maintenance infusion until birth to half of them.
Results: This present study showed that there is no difference between two group regarding (age, smoking, obesity, medical comorbidities, parity, history of abortion, mode of delivery gestational age, history of PTL, PROM, APHge, preeclampsia, IUGR, Mg sulfate toxicity, SBP and DBP). Neonatal outcome between two groups did not affected with difference Mg sulfate regimens. Intubation was done to (12 in first group and 11 in second group) neonates due to their respiratory distress. IVHge occurred in 7 neonates (5 in first group and 2 in second group). 10 neonates were died. No difference between two groups regarding kidney, liver function tests and CBC).
Conclusion: In women with preterm deliveries, using bolus dose of MgSO4 therapy is sufficient and has an equal effect to bolus and infusion protocol on Apgar score of neonate, which decrease costs, and side effects of MgSO4 therapy